Advanced in Heart Failure

Lihua P. Zhang

NHC Key Laboratory Of Clinical Research For Cardiovascular Medications, State Key Laboratory Of Cardiovascular Disease Fuwai Hospital, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
Advanced in Heart Failure
NHC Key Laboratory Of Clinical Research For Cardiovascular Medications, State Key Laboratory Of Cardiovascular Disease Fuwai Hospital, Chinese Academy Of Medical Sciences And Peking Union Medical College, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Lihua Zhang practices in Beijing, China. Zhang is rated as an Advanced expert by MediFind in the treatment of Heart Failure. Their top areas of expertise are Heart Failure, Chronic Myelogenous Leukemia (CML), Heart Failure with Preserved Ejection Fraction (HFpEF), Heart Bypass Surgery, and Aortic Valve Replacement.

Their clinical research consists of co-authoring 57 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 34 articles in the study of Heart Failure.

Locations

NHC Key Laboratory Of Clinical Research For Cardiovascular Medications, State Key Laboratory Of Cardiovascular Disease Fuwai Hospital, Chinese Academy Of Medical Sciences And Peking Union Medical College, Beijing, China
Other Locations
State Key Laboratory Of Cardiovascular Disease, Chinese Academy Of Medical Sciences And Peking Union Medical College, Shilongxi Road, Mentougou, 102308, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

57 Total Publications

Rationale and design of SCOPE trial: a prospective, multicentre, open-label, randomised controlled trial to evaluate the overall efficacy and safety of a short-term anticoagulation strategy versus conventional single antiplatelet therapy in patients with severe aortic stenosis without indications for anticoagulation or dual antiplatelet therapy post-transcatheter aortic valve replacement.
Rationale and design of SCOPE trial: a prospective, multicentre, open-label, randomised controlled trial to evaluate the overall efficacy and safety of a short-term anticoagulation strategy versus conventional single antiplatelet therapy in patients with severe aortic stenosis without indications for anticoagulation or dual antiplatelet therapy post-transcatheter aortic valve replacement.
Journal: BMJ open
Published: August 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Zhang's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile